Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12074440 | 1.00 | MEN1 (0.42) | MEN1KMT2AALKNR1H2NR1H3 | |
| SCHEMBL14936065 | 0.90 | ALK (0.42) | ALKHTTGPR119MAPTKIT | |
| SCHEMBL9999110 | 0.90 | ALK (0.42) | ALKHTTGPR119MAPTKIT | |
| SCHEMBL14936024 | 0.81 | TRPV1 (0.43) | — | |
| SCHEMBL14935781 | 0.81 | TRPV1 (0.43) | — | |
| SCHEMBL14935782 | 0.81 | TRPV1 (0.43) | — | |
| SCHEMBL19212337 | 0.79 | MEN1 (0.51) | MEN1KMT2ANR1H2NR1H3SMN1; SMN2 | |
| SCHEMBL899444 | 0.78 | MEN1 (0.54) | MEN1KMT2ANR1H2NR1H3SMN1; SMN2 | |
| SCHEMBL30223144 | 0.78 | MEN1 (0.54) | MEN1KMT2ANR1H2NR1H3SMN1; SMN2 | |
| SCHEMBL29268346 | 0.75 | MEN1 (0.50) | MEN1KMT2ANR1H2NR1H3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921373-B2 | Compounds having TRPV1 antagonistic activity and uses thereof | SHIONOGI & CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | PURDUE PHARMA L.P. | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | TRPV1, TRPA1, TRPV2 | MEN1 4737/4885KMT2A 4676/4885ALK 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.